See BOXED WARNINGS, WARNINGS and PRECAUTIONS
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In the two ESTRING controlled studies, discontinuation of treatment due to an adverse event was required by 5.4 percent of patients receiving ESTRING and 3.9 percent of patients receiving conjugated estrogens vaginal cream. The most common reasons for withdrawal from ESTRING treatment due to an adverse event were vaginal discomfort and gastrointestinal symptoms.
The adverse events reported with a frequency of 3 percent or greater in the two pivotal controlled studies by patients receiving ESTRING or conjugated estrogens vaginal cream are listed in Table 4.
| ADVERSE EVENT | ESTRING (n = 257) % | Conjugated Estrogens Vaginal Cream (n = 129) % |
|---|---|---|
Musculoskeletal | ||
Back Pain | 6 | 8 |
Arthritis | 4 | 2 |
Arthralgia | 3 | 5 |
Skeletal Pain | 2 | 4 |
CNS/Peripheral Nervous System | ||
Headache | 13 | 16 |
Psychiatric | ||
Insomnia | 4 | 0 |
Gastrointestinal | ||
Abdominal Pain | 4 | 2 |
Nausea | 3 | 2 |
Respiratory | ||
Upper Respiratory Tract Infection | 5 | 6 |
Sinusitis | 4 | 3 |
Pharyngitis | 1 | 3 |
Urinary | ||
Urinary Tract Infection | 2 | 7 |
Female Reproductive | ||
Leukorrhea | 7 | 3 |
Vaginitis | 5 | 2 |
Vaginal Discomfort/Pain | 5 | 5 |
Vaginal Hemorrhage | 4 | 5 |
Asymptomatic Genital Bacterial Growth | 4 | 6 |
Breast Pain | 1 | 7 |
Resistance Mechanisms | ||
Genital Moniliasis | 6 | 7 |
Body as a Whole | ||
Flu-Like Symptoms | 3 | 2 |
Hot Flushes | 2 | 3 |
Allergy | 1 | 4 |
Miscellaneous | ||
Family Stress | 2 | 3 |
Cases of toxic shock syndrome (TSS) have been reported in women using vaginal rings. TSS is a rare, but serious disease that may cause death. Warning signs of TSS include fever, nausea, vomiting, diarrhea, muscle pain, dizziness, faintness, or a sunburn-rash on face and body.
Vaginal erosion, vaginal ulceration, adherence of the vaginal ring to the vaginal wall:
Vaginal wall ulceration or erosion should be carefully evaluated. If an ulceration or erosion has occurred, consideration should be given to leaving the ring out and not replacing it until healing is complete in order to prevent the ring from adhering to the healing tissue.
Cases of bowel obstruction and vaginal ring use have been reported. Persistent abdominal complaints consistent with obstruction should be carefully evaluated.
Cases of hypersensitivity have been reported.
The following additional adverse events were reported at least once by patients receiving ESTRING in the worldwide clinical program, which includes controlled and uncontrolled studies. A causal relationship with ESTRING has not been established.
Body as a Whole: allergic reaction
CNS/Peripheral Nervous System: dizziness
Gastrointestinal: enlarged abdomen, vomiting
Metabolic/Nutritional Disorders: weight decrease or increase
Musculoskeletal: arthropathy (including arthrosis)
Psychiatric: depression, decreased libido, nervousness
Reproductive: breast engorgement, breast enlargement, intermenstrual bleeding, genital edema, vulval disorder
Skin/Appendages: pruritus, pruritus ani
Urinary: micturition frequency, urethral disorder
Vascular: thrombophlebitis
Vision: abnormal vision
See BOXED WARNINGS, WARNINGS and PRECAUTIONS
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In the two ESTRING controlled studies, discontinuation of treatment due to an adverse event was required by 5.4 percent of patients receiving ESTRING and 3.9 percent of patients receiving conjugated estrogens vaginal cream. The most common reasons for withdrawal from ESTRING treatment due to an adverse event were vaginal discomfort and gastrointestinal symptoms.
The adverse events reported with a frequency of 3 percent or greater in the two pivotal controlled studies by patients receiving ESTRING or conjugated estrogens vaginal cream are listed in Table 4.
| ADVERSE EVENT | ESTRING (n = 257) % | Conjugated Estrogens Vaginal Cream (n = 129) % |
|---|---|---|
Musculoskeletal | ||
Back Pain | 6 | 8 |
Arthritis | 4 | 2 |
Arthralgia | 3 | 5 |
Skeletal Pain | 2 | 4 |
CNS/Peripheral Nervous System | ||
Headache | 13 | 16 |
Psychiatric | ||
Insomnia | 4 | 0 |
Gastrointestinal | ||
Abdominal Pain | 4 | 2 |
Nausea | 3 | 2 |
Respiratory | ||
Upper Respiratory Tract Infection | 5 | 6 |
Sinusitis | 4 | 3 |
Pharyngitis | 1 | 3 |
Urinary | ||
Urinary Tract Infection | 2 | 7 |
Female Reproductive | ||
Leukorrhea | 7 | 3 |
Vaginitis | 5 | 2 |
Vaginal Discomfort/Pain | 5 | 5 |
Vaginal Hemorrhage | 4 | 5 |
Asymptomatic Genital Bacterial Growth | 4 | 6 |
Breast Pain | 1 | 7 |
Resistance Mechanisms | ||
Genital Moniliasis | 6 | 7 |
Body as a Whole | ||
Flu-Like Symptoms | 3 | 2 |
Hot Flushes | 2 | 3 |
Allergy | 1 | 4 |
Miscellaneous | ||
Family Stress | 2 | 3 |
Cases of toxic shock syndrome (TSS) have been reported in women using vaginal rings. TSS is a rare, but serious disease that may cause death. Warning signs of TSS include fever, nausea, vomiting, diarrhea, muscle pain, dizziness, faintness, or a sunburn-rash on face and body.
Vaginal erosion, vaginal ulceration, adherence of the vaginal ring to the vaginal wall:
Vaginal wall ulceration or erosion should be carefully evaluated. If an ulceration or erosion has occurred, consideration should be given to leaving the ring out and not replacing it until healing is complete in order to prevent the ring from adhering to the healing tissue.
Cases of bowel obstruction and vaginal ring use have been reported. Persistent abdominal complaints consistent with obstruction should be carefully evaluated.
Cases of hypersensitivity have been reported.
The following additional adverse events were reported at least once by patients receiving ESTRING in the worldwide clinical program, which includes controlled and uncontrolled studies. A causal relationship with ESTRING has not been established.
Body as a Whole: allergic reaction
CNS/Peripheral Nervous System: dizziness
Gastrointestinal: enlarged abdomen, vomiting
Metabolic/Nutritional Disorders: weight decrease or increase
Musculoskeletal: arthropathy (including arthrosis)
Psychiatric: depression, decreased libido, nervousness
Reproductive: breast engorgement, breast enlargement, intermenstrual bleeding, genital edema, vulval disorder
Skin/Appendages: pruritus, pruritus ani
Urinary: micturition frequency, urethral disorder
Vascular: thrombophlebitis
Vision: abnormal vision
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5Pm ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.